Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.

15:39 19/04/2026

Kangyuan Pharmaceutical (600557.SH) announced that the company has recently received the "Drug Clinical Trial Approval Notice" for Qing Shen Tong Luo Granules issued by the National Medical Products Administration. The approval conclusion for Qing Shen Tong Luo Granules is: in accordance with the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the clinical trial application for Qing Shen Tong Luo Granules submitted on January 28, 2026 meets the relevant requirements for drug registration. With further improvement of the clinical trial protocol, it is approved to conduct confirmatory clinical trials (Phase III clinical trials) for the treatment of rheumatoid arthritis with damp-heat obstruction syndrome.

Jiangsu Kanion Pharmaceutical (600557.SH) announced that the company has recently received the Drug Clinical Trial Approval Notice for QingShen TongLuo Granules issued by the National Medical Products Administration. The approval conclusion for QingShen TongLuo Granules states: According to the Drug Administration Law of the People's Republic of China and relevant regulations, after reviewing the clinical trial application for QingShen TongLuo Granules submitted on January 28, 2026, it meets the relevant requirements for drug registration. With further improvement of the clinical trial plan, it is approved to carry out confirmatory clinical trials (Phase III clinical trials) for the treatment of rheumatoid arthritis with damp-heat obstruction syndrome.

Chengdu Kanghong Pharmaceutical Group's subsidiary, KHN921 injection, has received approval from the US FDA to conduct clinical trials.

Auntie Jenny (02589): Shareholders voluntarily extend the lock-up period.

TCL ELECTRONICS (01070) announces profit growth. It is expected that the adjusted net profit attributable to shareholders in the first quarter will be approximately HK$3.6 billion to HK$4.0 billion, representing a year-on-year increase of approximately 125% to 150%.

Chengdu Kanghong Pharmaceutical Group's subsidiary, KHN921 injection, has received approval from the US FDA to conduct clinical trials.

Auntie Jenny (02589): Shareholders voluntarily extend the lock-up period.